Pneumrx

 
 

News & Press Releases

PneumRx, a BTG International group company, is focused on developing minimally invasive solutions for unmet medical needs in pulmonary medicine. Please click on a link below to learn more about PneumRx and PneumRx Coils.

 
 

Big Breakthrough for Emphysema Patients

December 16, 2013

It's estimated that three million Americans suffer from severe Emphysema.

Read Article

Your Health First Radio: Dr. Tim Connolly Discusses COPD and Emphysema

November 24, 2013

Your Health First Radio: Dr. Tim Connolly Discusses COPD and Emphysema

Read Article

Local doctors breathing new life into COPD treatment

November 15, 2013

It’s a debilitating disease that literally takes your breath away. Now local doctors are testing a device that may breathe life into the search for a less-invasive treatment for COPD.

Read Article

First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema

February 25, 2013

PneumRx, Inc., a leader in interventional pulmonology, announced the first U.S. patients treated with PneumRx’s Lung Volume Reduction Coils (LVRCs) for severe emphysema. Dr. Charlie Strange, of the Medical University of South Carolina, and Dr. Frank Sciurba, of the University of Pittsburgh and UPMC, treated the first US patients in the FDA-approved RENEW Study. The RePneu® LVRC, a minimally invasive medical implant designed to treat the symptoms of severe emphysema, is intended to improve lung function, exercise ability and quality of life for this underserved patient population.

Read Press Release

UMCG Enrolls First Patients in PneumRx RENEW Pivotal Trial for Treatment of Severe Emphysema

December 17, 2012

PneumRx, Inc., a leader in interventional pulmonology, announced today that University Medical Center Groningen has enrolled and treated the first patients in the FDA-approved RENEW pivotal trial to evaluate the RePneu Lung Volume Reduction Coil (LVRC). The RePneu LVRC, a minimally invasive medical implant designed to treat the symptoms of severe emphysema, is intended to improve lung function, exercise ability and quality of life for this underserved patient population.

Read Press Release

French Government Agrees to Fund Study of the PneumRx RePneu Lung Volume Reduction Coil

July 30, 2012

French Government commits 1.3 Million Euros to fund cost-effectiveness study of the RePneu LVRC in 100 subjects at 10 centers throughout France

Read Press Release

PneumRx, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of RePneu Lung Volume Reduction System

May 15, 2012

PneumRx, Inc. (www.pneumrx.com), a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has received FDA approval to commence a 30-site pivotal clinical trial to support a PMA application for the RePneu LVRC System.

Read Press Release

PneumRX, Inc. Raises $33 Million in Capital

January 04, 2011

Funds will be used to support European sales of the PneumRx RePneu Lung Volume Reduction Coil (LVRC) System and to conduct a Pivotal Clinical Trial to support a PMA Application.

Read Press Release

PneumRx Gets CE Mark for Lung Volume Reduction Coil System

October 13, 2010

PneumRX has received CE Marking for its RePneu Lung Volume Reduction Coil System to treat late stage emphysema. The device is designed to implant coils into the lungs to compress damaged tissue and restore elasticity in healthier lung tissue. The system is a minimally invasive alternative to surgery, according to the company. PneumRX intends to launch the product in Europe later this year.

Read Press Release